Included Health vs Labcorp
Side-by-side comparison of AI visibility scores, market position, and capabilities
Included Health provides comprehensive health navigation and care delivery for employers, specializing in complex conditions, mental health, and LGBTQ+ healthcare needs.
About
Included Health is a digital health company formed through the 2021 merger of Grand Rounds Health and Doctor On Demand, creating a unified platform for health navigation and virtual care delivery for employer health plans. The company provides members with access to expert second opinions, specialist referrals, primary care, mental health services, and benefits navigation through a single integrated platform. Included Health has built specialized expertise in serving populations with complex care needs including members with serious diagnoses, those seeking LGBTQ+-affirming care, and employees navigating mental health challenges. The company raised over $300M and serves large self-insured employers as a comprehensive health benefit that supplements traditional insurance. The merger combined Grand Rounds' navigation and expert medical opinion capabilities with Doctor On Demand's virtual primary care and psychiatry platform, creating broader clinical coverage than either company offered independently. Included Health positions itself as a health equity platform that improves outcomes for all employees regardless of their health complexity, geographic location, or demographic characteristics.
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
About
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.